Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Cataldo Patruno; Luca Stingeni; Katharina Hansel; Silvia Mariel Ferrucci; Simona Tavecchio; Gabriella Fabbrocini; Steven Paul Nisticò; Caterina Foti; Serena De Prezzo; Maddalena Napolitano

doi:10.1111/dth.13290

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Cataldo Patruno, Luca Stingeni, Katharina Hansel, Silvia Mariel Ferrucci, Simona Tavecchio, Gabriella Fabbrocini, Steven Paul Nisticò, Caterina Foti, Serena De Prezzo, Maddalena Napolitano

Research output: Contribution to journal › Article › peer-review

Abstract

Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

Original language	English
Article number	e13290
Journal	Dermatologic Therapy
Volume	33
Issue number	3
DOIs	https://doi.org/10.1111/dth.13290
Publication status	Published - 2020

Keywords

adult atopic dermatitis
dupilumab
nummular eczema
phenotype

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/dth.13290

Cite this

@article{e9338962dcf04734a8214c5ae674bbac,

title = "Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults",

abstract = "Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.",

keywords = "adult atopic dermatitis, dupilumab, nummular eczema, phenotype",

author = "Cataldo Patruno and Luca Stingeni and Katharina Hansel and Ferrucci, {Silvia Mariel} and Simona Tavecchio and Gabriella Fabbrocini and Nistic{\`o}, {Steven Paul} and Caterina Foti and {De Prezzo}, Serena and Maddalena Napolitano",

year = "2020",

doi = "10.1111/dth.13290",

language = "English",

volume = "33",

journal = "Dermatologic Therapy",

issn = "1396-0296",

publisher = "Blackwell Publishing Inc.",

number = "3",

}

TY - JOUR

T1 - Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

AU - Patruno, Cataldo

AU - Stingeni, Luca

AU - Hansel, Katharina

AU - Ferrucci, Silvia Mariel

AU - Tavecchio, Simona

AU - Fabbrocini, Gabriella

AU - Nisticò, Steven Paul

AU - Foti, Caterina

AU - De Prezzo, Serena

AU - Napolitano, Maddalena

PY - 2020

Y1 - 2020

N2 - Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

AB - Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

KW - adult atopic dermatitis

KW - dupilumab

KW - nummular eczema

KW - phenotype

UR - http://www.scopus.com/inward/record.url?scp=85081750825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081750825&partnerID=8YFLogxK

U2 - 10.1111/dth.13290

DO - 10.1111/dth.13290

M3 - Article

C2 - 32125741

AN - SCOPUS:85081750825

SN - 1396-0296

VL - 33

JO - Dermatologic Therapy

JF - Dermatologic Therapy

IS - 3

M1 - e13290

ER -

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this